Focus
Towards new milestones – Elicera's plan for 2025 and 2026
Elicera Therapeutics Q1 report highlights promising initial clinical data from the CARMA study with ELC-301, stable patient recruitment and preparations for...
Annexin summarizes Q1: promising study data and fully subscribed issue
Annexin Pharmaceuticals has started 2025 with clear progress...
Clinical progress and capital injection strengthen Alzinova's Phase II plans
Alzinova started 2025 with clear progress in the development...
The Science Behind ColdZyme – Insights from Professors
A study with athletes has shown that Enzymaticas...
AI models analyze health data from 177 million patients
Researchers at University College London and King's College...
Roche may reconsider $50 billion investment in the US
Swiss pharmaceutical giant Roche is considering reevaluating its...
Biosergen strengthens the board with an expert in anti-infective drugs
Biosergen, a biotechnology company focused on the development of...
Trump wants to cut drug prices by up to 80 percent
President Donald Trump intends to sign an executive order...
Age Labs on the collaboration with Lipum: "We want to enable precision medicine in RA"
Lipum and Norwegian diagnostics company Age Labs collaborate to...
Biosergen takes aim at climate-driven fungal infections
Research shows that climate change is driving the rapid...
Mentice's CEO: "We anticipate a further ramp up in our sales"
Mentice reported strong growth in the first quarter...
BioInvent receives FDA Fast Track Designation for BI-1808
BioInvent has published its interim report for Q1 2025,...
Notes
Alligator Bioscience receives FDA approval for phase III mitazalimab dose
Lena Åredal appointed new CEO of SyntheticMR
BioArctic advances phase IIa study with exidavnemab
Novo Nordisk advances amycretin to Phase III
BioNTech acquires CureVac for $1,25 billion
NEWSLETTER
NEWS
AstraZeneca in billion-dollar deal in AI
Kancera rises on positive results from the KANDOVA study
New success strengthens Alzinova's licensing opportunities for ALZ-101
Upcoming events!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
Bispecific and Chinese the new black in cancer
The venture capital cycle is complete – we are back where we started
